FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an anti-CD3 antibody or an antigen-binding fragment of an antibody. Also disclosed is a nucleic acid coding said antibody, an expression vector, a host cell for expressing said antibody, a pharmaceutical composition containing said antibody, an anti-CD3 chimeric antigen CAR receptor. Disclosed is a method of treating the disorder in a mammal using said antibody.
EFFECT: invention makes it possible to effectively treat disorders in a mammal using said antibody.
51 cl, 1 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH 4-1BB AGONIST | 2019 |
|
RU2788524C2 |
| CHIMERIC ANTIGEN RECEPTOR WITH COSTIMULATORY DOMAIN 4-1BB | 2020 |
|
RU2830540C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| DOSING REGIMEN FOR A HYBRID PROTEIN GP100-SPECIFIC REDIRECTING TCR-ANTI-CD3 SCFV | 2017 |
|
RU2766119C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| SUBSTRATES OF MATRIX METALLOPROTEINASE AND OTHER CLEAVABLE MOIETIES AND METHODS FOR USE THEREOF | 2014 |
|
RU2715232C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
